DekaBank Deutsche Girozentrale held its position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 20,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. DekaBank Deutsche Girozentrale’s holdings in Dynavax Technologies Corporation were worth $200,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. CAPROCK Group Inc. bought a new position in Dynavax Technologies Corporation during the second quarter valued at $134,000. Fox Run Management L.L.C. bought a new position in Dynavax Technologies Corporation during the second quarter valued at $158,000. Bank of America Corp DE increased its position in Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 456 shares in the last quarter. American International Group Inc. increased its position in Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,584 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares in the last quarter. 60.23% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 17.20 on Thursday. The firm has a 50-day moving average price of $13.47 and a 200 day moving average price of $8.01. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $19.60. The company’s market cap is $941.65 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter in the prior year, the company posted ($0.75) EPS. Equities research analysts predict that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/31/dekabank-deutsche-girozentrale-continues-to-hold-stake-in-dynavax-technologies-corporation-dvax.html.

Several equities analysts have recently weighed in on the company. Cowen and Company reissued an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Thursday, August 10th. Royal Bank Of Canada raised Dynavax Technologies Corporation from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $7.00 to $26.00 in a research report on Monday, July 31st. William Blair reissued an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. J P Morgan Chase & Co raised Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $27.00 in a research report on Monday, July 31st. Finally, BidaskClub downgraded Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Dynavax Technologies Corporation has an average rating of “Hold” and a consensus price target of $23.34.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.